Market Closed -
Xetra
11:35:17 2024-04-23 am EDT
5-day change
1st Jan Change
14.18
EUR
+3.50%
+2.90%
-33.36%
Evotec SE : Notification and public disclosure of transactions by persons
June 23, 2020 at 10:40 am EDT
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
23.06.2020 / 16:38
The issuer is solely responsible for the content of this announcement.
1. Details of the person discharging managerial responsibilities / person closely associated
a) Name
Title:
Dr. First name:
Werner Last name(s):
Lanthaler
2. Reason for the notification
a) Position / status
Position:
Member of the managing body
b) Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name
b) LEI
4. Details of the transaction(s)
a) Description of the financial instrument, type of instrument, identification code
Type:
Share ISIN:
DE0005664809
b) Nature of the transaction
Exercise against cash settlement (Share Performance Plan) Transaction linked to the exercise of share option programmes
c) Price(s) and volume(s)
Price(s)
Volume(s) 24.2403 EUR
1005390.68 EUR
d) Aggregated information
Price
Aggregated volume 24.2403 EUR
1005390.68 EUR
e) Date of the transaction
f) Place of the transaction
23.06.2020 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language:
English Company:
Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany Internet:
www.evotec.com
End of News
DGAP News Service
60833 23.06.2020
Evotec Taps Christian Wojczewski as New CEO
Apr. 23
MT
Germany's Evotec appoints Christian Wojczewski as CEO
Apr. 23
RE
Evotec finds permanent CEO solution: Christian Wojczewski takes over from July 1
Apr. 23
DP
Evotec, Variant Bio Team Up to Develop Treatment for Fibrosis
Apr. 18
MT
Evotec, Variant Bio Launch Partnership to Develop Treatments for Fibrosis
Apr. 18
MT
Evotec Names First Chief People Officer
Apr. 17
MT
Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024
Apr. 17
CI
Deutsche Bank raises Evotec to 'Buy' - Frustration after CEO departure overcome
Apr. 12
DP
STOXX 600 climbs over 1% on rate-cut optimism
Apr. 12
RE
Deutsche Bank Research raises Evotec to 'Buy' - Target 19 Euro
Apr. 12
DP
EVOTEC : Deutsche Bank takes a positive view
Apr. 12
ZD
U.S. Futures, European Stocks Up as ECB Signals Moving Closer to Rate Cut
Apr. 12
DJ
EVOTEC : Receives a Buy rating from Jefferies
Mar. 28
ZD
Aeovian Pharmaceuticals, Inc. announced that it has received $87 million in funding from Sofinnova Investment, Inc., Evotec SE, venBio LLC, Apollo Health Ventures, b2venture AG, Hevolution Foundation
Mar. 27
CI
Aeovian Pharmaceuticals, Inc. announced that it has received $50 million in funding from Hevolution Foundation, Apollo Health Ventures, Sofinnova Investment, Inc., venBio LLC, Evotec SE, b2venture AG
Mar. 27
CI
Tubulis Technologies announced that it has received ?128 million in funding from a group of investors
Mar. 13
CI
Evotec Grants Claris Ventures Portfolio Biotech Firms Access to Testing Platform
Mar. 06
MT
EVOTEC : Warburg Research maintains a Buy rating
Mar. 05
ZD
Sector Update: Health Care Stocks Advance in Afternoon Trading
Feb. 07
MT
Evotec Unit, Advanced BioScience Expand Agreement to Develop Antibodies Against HIV
Feb. 07
MT
Evotec's US Unit Expands Collaboration vs HIV with Advanced BioScience Laboratories
Feb. 07
MT
EVOTEC : RBC remains its Buy rating
Jan. 26
ZD
Jefferies lowers target for Evotec to 28 Euro - 'Buy'
Jan. 26
DP
EVOTEC : Jefferies remains its Buy rating
Jan. 26
ZD
Global markets live: Crest Nicholson, Gilead, United Airlines, 3M Company, General Electric...
Jan. 23
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women's health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
More about the company
Last Close Price
13.7
EUR
Average target price
25.4
EUR
Spread / Average Target
+85.40%
Consensus
1st Jan change
Capi.
-33.36% 2.59B +3.13% 42.11B +48.83% 40.08B +8.49% 40B -10.82% 26.87B +8.26% 24.58B -23.69% 18.44B +1.58% 11.94B +32.83% 11.66B +6.63% 11.01B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1